Rep. Jack Bergman (R-Mich.) stated Tuesday that current political conditions favor advancing psychedelic treatment research, citing President Trump's recent support for the field.

Bergman made his remarks at The Hill's "Rethinking Psychedelic Treatment for America's Mental Health Crisis" event, which was sponsored by Definium Therapeutics. The congressman serves as co-founder and co-chair of Congressional Psychedelics Advancing Therapies (PATH), a bipartisan caucus focused on psychedelic research policy.

"The time is now" to push for breakthroughs in psychedelic treatments, Bergman said, pointing to what he described as favorable political momentum under the Trump administration.

The congressional caucus has been working to advance research into psychedelic substances as potential treatments for mental health conditions including depression, PTSD, and anxiety disorders. Several clinical trials are currently underway examining substances like psilocybin and MDMA for therapeutic applications.

The event highlighted ongoing efforts in Congress to establish regulatory frameworks that could facilitate expanded research while maintaining safety protocols for experimental treatments.